Zofran (ondansetron) is not FDA-approved for use during pregnancy. The drug is approved only for preventing nausea and vomiting caused by chemotherapy, radiation, and surgery. When doctors prescribe it for morning sickness or hyperemesis gravidarum, they are using it off-label, meaning in a way not included in its official approved indications.
What Zofran Is Actually Approved For
The FDA approved ondansetron for two specific uses: preventing nausea and vomiting from cancer chemotherapy, and preventing postoperative nausea and vomiting. These are the only indications listed on the drug’s official label. Pregnancy-related nausea does not appear anywhere in the approved uses.
Ondansetron works by blocking serotonin receptors in the gut and brain that trigger the vomiting reflex. This mechanism makes it effective across different causes of nausea, which is partly why it became widely prescribed off-label for pregnant women despite never going through the FDA approval process for that purpose.
Why Doctors Prescribe It Anyway
Off-label prescribing is legal and common in medicine. It means a doctor uses their clinical judgment to prescribe a drug for a condition it wasn’t specifically tested and approved for. Zofran became popular for pregnancy nausea because it’s fast-acting and effective, especially for women with severe vomiting that doesn’t respond to other treatments.
Clinical guidelines from major hospitals position ondansetron as a fourth-line option for pregnancy nausea. That means it’s typically reserved for cases where other treatments have failed or aren’t tolerated. The usual off-label dose is 4 to 8 mg every 12 hours, with a maximum of 16 mg per day.
What the FDA Label Says About Pregnancy
The FDA’s current label acknowledges that ondansetron has been studied in pregnant animals without clear evidence of harm to the fetus, but it stops well short of calling the drug safe for pregnant women. The label states that “available data do not reliably inform the association of ZOFRAN and adverse fetal outcomes” and that published studies have reported “inconsistent findings” with “important methodological limitations.”
Zofran previously carried a Pregnancy Category B rating under the old FDA classification system, meaning animal studies showed no risk but human data was insufficient. The FDA has since replaced that letter system with more detailed narrative descriptions of the available evidence, but the core message remains the same: the data on pregnancy outcomes is incomplete and inconclusive.
The Concern About Birth Defects
The main safety question involves a possible small increase in the risk of cleft lip or cleft palate when ondansetron is used during the first trimester. A large retrospective study of over 1.8 million pregnancies found that oral cleft defects occurred in 14 out of every 10,000 babies exposed to ondansetron in the first trimester, compared to 11.1 out of every 10,000 unexposed babies. That translates to roughly 3 additional cases per 10,000 exposed pregnancies, or about a 24 percent relative increase in risk.
A second study of more than 864,000 mother-child pairs found a similar numerical increase, though the result was not statistically significant, meaning the increase could have been due to chance. The overall picture from research is that if there is a risk, it’s small in absolute terms but not definitively ruled out.
One thing that’s clearly established is that ondansetron does cross the placenta. A study measuring drug levels in fetal tissue during early pregnancy found ondansetron present in all embryonic compartments, with fetal concentrations reaching about 41 percent of maternal blood levels. This doesn’t automatically mean harm, but it confirms the fetus is exposed to the drug.
Which Medications Are FDA-Approved for Morning Sickness
The combination of doxylamine and pyridoxine (sold as Diclegis and Bonjesta) is the only prescription medication with actual FDA approval for treating nausea and vomiting during pregnancy. Doxylamine is an antihistamine and pyridoxine is vitamin B6. Together they work as a first-line treatment for morning sickness, and their safety profile during pregnancy has been studied more extensively than ondansetron’s.
For many women, vitamin B6 alone or combined with over-the-counter doxylamine is tried first. Ginger supplements and dietary changes are also commonly recommended as starting points. Ondansetron typically enters the picture only after these options have been tried and haven’t provided enough relief, particularly in cases of hyperemesis gravidarum, the severe form of pregnancy nausea that can lead to dehydration and weight loss.
What This Means in Practice
If your doctor has prescribed or suggested Zofran for pregnancy nausea, they’re making a clinical decision that the benefit of controlling your nausea outweighs the uncertain but likely small risks. This is especially common when vomiting is severe enough to affect your nutrition, hydration, or ability to function. The fact that a drug is used off-label doesn’t automatically make it dangerous, but it does mean the evidence supporting that specific use hasn’t met the FDA’s standard for formal approval.
The timing of use matters. The potential concern about cleft defects is specific to the first trimester, when facial structures are forming. Use during the second and third trimesters has not been linked to the same concerns, though the overall body of evidence remains limited. If you’re in the first trimester and considering ondansetron, the absolute risk of an oral cleft defect, even with the possible increase, remains below 0.2 percent.